<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260721070287N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-18</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of group training based on schema therapy on hope and anxiety in women with infertility undergoing in vitro fertilization treatment</public_title>
      <acronym>IVF</acronym>
      <scientific_title>Investigating the effect of group training based on schema therapy on hope and anxiety in women with infertility undergoing in vitro fertilization treatment</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-10-24</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>36</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/91932</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Other, Purpose: Supportive, Other design features: The present study is a controlled interventional (quasi-experimental) study designed to evaluate the effect of group schema therapy–based education on hope and anxiety among infertile women undergoing in vitro fertilization (IVF). Participants will be consecutively recruited from infertile women attending the Infertility Clinic of Shahid Akbarabadi Educational Hospital who meet the eligibility criteria. After providing written informed consent, participants will be randomly allocated to either the intervention or control group using a random numbers table.This clinic was selected as the study setting due to the accessibility of the target population and its willingness to collaborate with the research team. The sample size was calculated based on the estimated effect size reported in similar studies. Allowing for a minimum attrition rate of 10%, a total of 18 participants will be enrolled in each group.The educational intervention is based on Jeffrey Young's schema therapy approach, which was selected because of its emphasis on identifying and modifying early maladaptive schemas and their influence on cognitive, emotional, and behavioral patterns. The intervention will be delivered through structured educational sessions using cognitive, experiential, and behavioral techniques.The intervention will consist of twelve 90-minute sessions delivered both face-to-face and online. The educational content is based on the principles of schema therapy, adapted using evidence from studies conducted among infertile women, and supplemented with structured homework assignments. Participants in the control group will receive the routine care provided by the infertility center and, after completion of the study, will be provided with the schema therapy–based educational package.Outcome assessments will be performed at three time points: at baseline (before the intervention), immediately after completion of the twelfth intervention session, and four weeks after the end of the intervention. The primary outcome measures include hope, assessed using the Snyder Hope Scale, anxiety, assessed using the Beck Anxiety Inventory (BAI), and early maladaptive schemas, assessed using the Young Schema Questionnaire (YSQ).Data will be analyzed using SPSS software version 24. Between-group comparisons will be conducted using the independent-samples t-test, repeated-measures analysis, or analysis of covariance (ANCOVA), as appropriate. Potential confounding variables, including age, duration of infertility, cause of infertility (male or female factor), and type of infertility (primary or secondary), will be controlled for in the analyses. A two-sided p-value of less than 0.05 will be considered statistically significant, Randomization description: Participants who meet the inclusion criteria and are selected by the infertility specialist to undergo in vitro fertilization (IVF) after clinical evaluation will be randomly allocated to the intervention or control group using a random 
numbers table, following the provision of written informed consent.
Sampling Method: Continuous
Sampling will be conducted continuously. Participants will be assigned to either the intervention or control group using a table of random numbers. To this end, eligible individuals who have provided informed consent will be numbered from 1 to 18. From these, 18 numbers will be randomly selected and assigned to the intervention group, while the remaining 18 numbers will be assigned to the control group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>infertility.</hc_freetext>
      <i_freetext>Intervention group: Schema therapy-based educational intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is The protocol stipulates that the confidential data remains with the principal investigator; it may only be released upon a formal request and with the university's authorization, and will not be published as public data.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Mirzakhani Eshlaghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahran 2nd Roundabout, Siadat Alley</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1488874544</zip>
        <telephone>+98 21 4431 9831</telephone>
        <email>fatemehmirzakhaniseptember@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Mirzakhani Eshlaghi Mirzakhani Eshlaghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1488874544</zip>
        <telephone>+98 21 4473 8195</telephone>
        <email>fatemehmirzakhaniseptember@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1/Ability to read and write sufficiently to complete the study questionnaires.2/Confirmed diagnosis of infertility and selection for in vitro fertilization (IVF) by an infertility specialist.3/At least one year has elapsed since the diagnosis of infertility.4/ Age between 18 and 40 years.5/ No other physical or psychological disorders, based on self-report or documented medical records.6/No history of alcohol, illicit drug, or psychoactive substance use.7/Not currently using psychiatric medications.8/No experience of major stressful life events during the previous six months.9/No participation in infertility-related quality-of-life enhancement or psychological intervention programs during the previous six months.10/Undergoing the first IVF cycle.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Failure to attend at least two educational intervention sessions.a. Diagnosis of or development of a medical illness during the intervention period.b. Occurrence of major stressful events or unexpected acute life events (e.g., the death of a close family member) at any stage of the study, as determined by participants' self-report.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Schema therapy-based educational intervention</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Mean hope score on the Snyder scale, mean anxiety score on the Beck inventory, and mean schema score on the Young questionnaire. Timepoint: Before and immediately after the completion of 12 sessions, and 4 weeks after the intervention ended. Method of measurement: Young's Schema Questionnaire, Schneider's Hope Questionnaire, and Beck's Anxiety Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-08-31</approval_date>
        <contact_name>Ethics Committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Shahran 2nd Roundabout, Siadat Alley Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
